PROJECT

Projects

Environmental & Social Review Summary

Project Number

40144

Company Name

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.

Date ESRS Disclosed

Feb 7, 2018

Country

Mexico

Region

Latin America and the Caribbean

Last Updated Date

Jul 7, 2018

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Apr 25, 2018
Signed : May 20, 2018
Invested : Jul 2, 2018

Sector

Pharmaceuticals and Medicine

Industry

Health, Education and Life Sciences

Department

Regional Industry - MAS LAC

Project Description

Founded in 1996, Genomma Lab Internacional S.A.B. de C.V. ("Genomma" or the “Company” - http://www.genommalab.com/) is a Mexico based, pharmaceutical company listed in the Mexican Stock Exchange with presence in 19 countries across Latin America. It is focused on the marketing, distribution and sales of over-the-counter (“OTC”) or nonprescription medicines and personal care (“PC”) products.  The company does not manufacture any products yet, but works with more than 350 third-party contract manufacturers / co-packers that are US-FDA approved and/or have the approval of the local market where they sell their products. The company decided only recently to build its own in-house production capabilities.  

In 2017, Genomma acquired a 32-ha lot in the town of San Cayetano Morelos (Municipality of Toluca, State of Mexico) to build its first OTC and PC production facility ( https://goo.gl/maps/3ZPm8Gbw6WK2 ). Additionally, Genomma recently acquired a small pharmaceutical manufacturing facility in Mexico City for the initial production of several of their OTC brands. Both facilities will be only dedicated to finished formulations and all active pharmaceutical ingredients (APIs) will be procured externally. Genomma's distribution center, now located in a rental property in the Toluca Industrial Park will be relocated to the newly constructed facility. Genomma will occupy 16 ha for its new facility, and will subdivide the remaining area in 13 individual lots, which will be offered for sale to its main suppliers.

The purpose of IFC's proposed corporate financing is to support Genomma's approximately US$208.4 million expansion plan over the next 2 years which includes the construction of Genomma's first manufacturing facility, debt refinancing, and other capital expenditures (the “project”). IFC's proposed investment is a US$54 million corporate loan to finance the construction of Genomma's first manufacturing  facility in the state of Mexico, debt refinancing, and other capital expenditures .IFC is in early discussions with the company regarding a potential mobilization of additional financing resources.

Overview of IFC's Scope of Review

 IFC's review included meetings with Genomma's management team in Mexico including Chief Financial Officer, Vice President (VP) Sales,  VP Manufacturing and Mexico Country Manager , VP International Expansions and Corporate Social Responsibility (CSR), CSR Manager, Human Resources (HR) Manager, Legal Department, Project Management Team for new OTC and PC plant, OTC Plant Manager in Mexico City, Head of Quality, Physical Security Manager, Distribution Center Safety Officer. 

A site visit to Genomma's headquarters in Mexico City, distribution center in the industrial park of Toluca, and construction site of future OTC and PC production facility, was conducted during December 4-7, 2017. The due diligence also included a review of supporting documentation including Genomma's 2016 Sustainability Report, HR policies and procedures, collective agreements, contracts and payroll records, examples of contracts with third party-suppliers, audit checklist for OTC co-packers, training records, earthworks permit, industrial land use zoning permit etc.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan